Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc. benefits from a robust market for its integrated solutions, as indicated by the meaningful increase in Chromium reaction volumes, despite anticipated pricing pressures. The company's consumables are projected to grow significantly faster than instrument revenue, with estimates suggesting a 5-19x increase per platform by 2027. This growth trajectory reflects the ongoing demand for advanced biological analysis tools, positioning 10x Genomics favorably within the life science technology market.

Bears say

10x Genomics Inc has reported a contraction in 2024, with revenues impacted by double-digit pricing pressure and flat to modestly lower volumes, leading to a bleak growth outlook that does not expect to improve until 2027. Additionally, the company experienced weaker-than-expected Q4 results with an earnings per share miss and a full-year revenue outlook that fell below analyst expectations. Since its peak stock prices in 2021, 10x Genomics’s stock has declined over 90%, indicating that performance has not met market expectations, contributing to a negative outlook for the company's financial stability.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.